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patients were women receiving ‘fresh’ cycles of IVF/ICSI from
October 2001 to January 2006 at a UK ART unit that treats
National Health Service and privately funded patients. All
patients were treated with rFSH (Puregon™) for ovarian stimu-
lation. Rates of ongoing pregnancies per cycle and live birth rates
were calculated from clinic records. Drug use was determined
using pharmacy dispensing data. Costing for clinic procedures
was based on a ﬁnancial audit of the centre. Costs were applied
at UK 2007 prices. RESULTS: After excluding non IVF/ICSI
cycles, those lacking pharmacy data and complete cycle data we
analysed 1418 cycles undertaken by 1001 women. Mean dura-
tion of ovarian stimulation was 9.1 days (95%CI: 9.0–9.3 days).
The clinical pregnancy rate/cycle was 36.4% (95%CI: 33.9–
39%), the ongoing pregnancy rate was 24.4% (95%CI: 22.2%–
26.7%), and the live birth rate was 22% (95%CI: 19.7–24.2%).
The average rFSH dose/cycle prescribed was 1855 units (SD:
561), whereas the average dispensed dose/cycle was 1891 units
(SD: 540). The average cost of rFSH/cycle was £646 (SD: 219).
Average cost/cycle for concomitant medications and procedures
was £159 (SD: 122) and £2,127 (SD: 349), respectively. The
average total cost/cycle was £2.932 (SD: 422). The average cost/
clinical pregnancy, cost/ongoing pregnancy and cost/live birth
were £8,058, £12,017 and £13,326, respectively. CONCLU-
SIONS: While IVF/ICSI outcomes in this real-life clinical setting
were similar to UK averages, the cost of rFSH/cycle was lower
than that estimated in the NICE guidelines. These ﬁndings
suggest that NICE should revisit the affordability of funding
recommended levels of IVF/ICSI, taking efﬁcient drug delivery
practices into account.
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OBJECTIVES: To assess the long-term effects of growth
hormone (GH) treatment on physical features, safety and health-
related quality of life (HRQoL) in patients with the Prader-Willi
syndrome (PWS), as compared to general population. PWS is a
complex genetic disorder characterized by e.g. mental retarda-
tion, behavioral disorders, obesity, hypogonadism, and short
stature. METHODS: All 22 known Finnish paediatric patients
aged 2–10 years with PWS were contacted for participation in a
clinical study of one year between 1996 and 1998 for treatment
with GH (somatropin, 0.1 IU/kg/d); 20 patients participated.
Thereafter, they were treated in their own hospital districts with
various GH regimens. The subjects were invited to a follow-up
study consisting of one visit in 2007. Altogether 19 out of the 20
in the original study participated in the follow-up and underwent
a comprehensive evaluation, including HRQoL measurement by
the 16D. The 16D is a generic, comprehensive, 16-dimensional
(mobility, seeing, hearing, breathing, sleeping, eating, speech,
elimination, going to school, mental function, discomfort and
symptoms, depression, distress, vitality, appearance, and getting
and having friends), self-administered measure of HRQoL for
adolescents, and it can be used both as a proﬁle and single score
measure. Pre-existing data from 1995 of a sample of Finnish
age-matched population (n = 239) were used for comparison
using the independent samples t-test. Results for the physical
outcomes are reported separately. RESULTS: The mean 16D
score was 0.851 for the study patients and 0.949 for the com-
parator population; the difference is statistically signiﬁcant
(p = 0.001). The patients were worse off than the general popu-
lation on the dimensions of mobility, breathing, speech, mental
function, going to school, discomfort and symptoms, and getting
and having friends. CONCLUSIONS: Despite GH treatment, the
self-perceived HRQoL of these adolescent and young, adult PWS
patients remains poor on several dimensions and overall com-
pared with age-matched general population.
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OBJECTIVES: To assess the psychometric performance of the
Children’s Dermatology Quality of Life Index (CDQoL) in
Turkish pediatric dermatology patients. The CDQoL is a speciﬁc
quality of life index and which measures the impact of derma-
tology symptoms on QoL. METHODS: The health-related
quality of life (HRQoL) is measured in a sample of 90 patients
with dermatological problem using both the Turkish version of
the CDQoL and the Short Form 10 (SF-10) instruments.
RESULTS: The internal consistency within the domains of the
CDQoL was good, with Cronbach’s Alpha values 0.78 for the
CDQoL and 0.91 for the SF-10. Signiﬁcant correlations were
observed between the total scores of the CDQoL and the SF-10.
CONCLUSIONS: Overall, the results indicated that the psycho-
metric performance of the CDQoL in the study sample was quite
good and the instrument was found to be valid and reliable. The
instrument is likely to be suitable for use in clinical studies of
chronic dermatological diseases in Turkey.
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OBJECTIVES: The short, self administered Menopause Speciﬁc
Quality of Life Questionnaire (MSQoL) is a speciﬁc quality of
life instrument which measures the impact of menopause symp-
toms on QoL. This study aims to adapt the MSQoL question-
naire into Turkish (for Turkish) culture and check the
questionnaire psychometric properties. METHODS: The origi-
nal instrument was translated and back translated by two inde-
pendent translators. For psychometric measures, a small sample
was used to check the initial comprehension and factibility. Cron-
bach’s Alfa was used to assess reliability and factor analysis to
assess dimensionality. The EuroQol questionnaire and corre-
sponding Visual Analogue Scales were used for concurrent valid-
ity. RESULTS: 160 women with menapause syndrom were
participated. Mean age was 49. The reliability was good
(Alpha = 0.97) and all dimensions eigenvalues higher than 1.0,
explaning 78.9% of avaliable variability. All items loaded on
own dimensions. Correlations were moderate with EuroQol and
VAS. CONCLUSIONS: The Menapause Speciﬁc Quality of Life
Questionnaire has good psychometric properties. It is also cap-
able to discriminate women with a menapause.
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